While a €100 billion package is a serious commitment, Europe's largest energy-intensive industries will require far more than ...

NewAmsterdam Pharma (NAMS) outlook: obicetrapib could cut cardiovascular risk beyond LDL-C. Key catalysts into 2026–27; ...

John Paulson’s Q1 2026 13F portfolio decreased to ~$3.11B, concentrated in nine securities, with the top five making up ~87%.

Greenlight Capital's 13F portfolio rose from $2.85B to $3.19B in Q1 2026, outperforming the S&P 500 with a 6.5% return vs. -4 ...

ETB's 8.15% distribution yield is attractive and tax-efficient, making it suitable for taxable accounts. Read why ETB is ...

A high-level overview of Dow Jones Futures (INDU) stock. View (INDU) real-time stock price, chart, news, analysis, analyst reviews and more.

A high-level overview of United States 10-Year Bond Yield (US10Y) stock. View (US10Y) real-time stock price, chart, news, analysis, analyst reviews and more.

Neocloud stocks after the sell-off: see why analysts favor Applied Digital (APLD) and Nebius (NBIS). Read more here.

Compare 12%-yielding tech lenders HTGC vs. TRIN at 1.3x NAV—pros, cons, and which fits your portfolio. Click to read more.

Gold Royalty (GROY) shifts to cash-flow compounding as acquisitions boost near-term revenue and long-term growth.

Kimbell Royalty Partners (KRP) is upgraded to Buy following two accretive acquisitions funded without incremental debt.

Axon Q1 beats and raises 2025 revenue growth to 30–32%, but weak FCF and cash conversion risks persist. Click to read more ...